Healthcare [ 2/11 ] | Biotechnology [ 32/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 21, 22 | -0.47
Increased by
+48.91%
|
-0.17
Decreased by
-176.47%
|
Aug 16, 22 | -0.45
Increased by
+76.80%
|
-0.06
Decreased by
-650.00%
|
May 16, 22 | -0.44
Increased by
+10.20%
|
-0.51
Increased by
+13.73%
|
Apr 1, 22 | -0.92
Decreased by
-19.48%
|
-0.41
Decreased by
-124.39%
|
Mar 31, 22 | -0.92
Decreased by
-55.93%
|
-0.41
Decreased by
-124.39%
|
Nov 10, 21 | -1.94
Decreased by
-198.46%
|
-0.51
Decreased by
-280.39%
|
Aug 12, 21 | -0.49
Decreased by
-4.26%
|
-0.63
Increased by
+22.22%
|
May 11, 21 | -0.77
Decreased by
-5.48%
|
-0.62
Decreased by
-24.19%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-8.24 M
Decreased by
N/A%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 292.00 K
Increased by
+N/A%
|
-7.98 M
Decreased by
N/A%
|
Decreased by
-2.73 K%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-7.77 M
Decreased by
N/A%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 570.00 K
Increased by
+N/A%
|
-10.23 M
Decreased by
N/A%
|
Decreased by
-1.79 K%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
0.00
Decreased by
N/A%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
0.00
Decreased by
N/A%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
0.00
Decreased by
N/A%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
0.00
Decreased by
N/A%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.